利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.018 秒)

    In vivo chemosensitivity screen for human tumors
    3.
    发明授权
    In vivo chemosensitivity screen for human tumors 失效

    公开(公告)号：US06620403B2

    公开(公告)日：2003-09-16

    申请号：US09841669

    申请日：2001-04-24

    申请人： Roman Perez-Soler

    发明人： Roman Perez-Soler

    IPC分类号： A61K4900

    CPC分类号： A61K49/0008 ,  A01K2217/05 ,  C07K14/4701

    摘要： A method of evaluating the chemosensitivity of a tumor to an anti-tumor agent in vivo is provided. The method comprises extracting a portion of a tumor from a human host and inserting the portion of the tumor into an immunodeficient mouse. The tumor portion is permitted to grow to a minimum preselected size to form a test tumor. An amount of an anti-tumor agent is administered to the immunodeficient mouse sufficient to determine whether the anti-tumor agent is effective in treating the test tumor. The anti-tumor activity of the anti-tumor agent on the test tumor is assessed.

    In vivo chemosensitivity screen for human tumors
    4.
    发明申请
    In vivo chemosensitivity screen for human tumors 失效
    人类肿瘤的体内化学敏感性筛选

    公开(公告)号：US20020031473A1

    公开(公告)日：2002-03-14

    申请号：US09841669

    申请日：2001-04-24

    发明人： Roman Perez-Soler

    IPC分类号： A61K049/00 ,  A01K067/00

    CPC分类号： A61K49/0008 ,  A01K2217/05 ,  C07K14/4701

    摘要： A method of evaluating the chemosensitivity of a tumor to an anti-tumor agent in vivo is provided. The method comprises extracting a portion of a tumor from a human host and inserting the portion of the tumor into an immunodeficient mouse. The tumor portion is permitted to grow to a minimum preselected size to form a test tumor. An amount of an anti-tumor agent is administered to the immunodeficient mouse sufficient to determine whether the anti-tumor agent is effective in treating the test tumor. The anti-tumor activity of the anti-tumor agent on the test tumor is assessed.

    摘要翻译： 提供了一种在体内评估肿瘤对抗肿瘤剂的化学敏感性的方法。 该方法包括从人宿主中提取肿瘤的一部分并将该部分肿瘤插入免疫缺陷小鼠。 允许肿瘤部分生长至最小预选大小以形成测试肿瘤。 向免疫缺陷小鼠施用足量的抗肿瘤剂量以确定抗肿瘤剂是否有效治疗试验肿瘤。 评估抗肿瘤剂对测试肿瘤的抗肿瘤活性。

    Novel response element
    8.
    发明申请
    Novel response element 审中-公开
    新颖的回应元素

    公开(公告)号：US20030143583A1

    公开(公告)日：2003-07-31

    申请号：US10261517

    申请日：2002-10-01

    申请人： Biovitrum AB, a Swedish corporation

    发明人： Isabel Climent-Johansson ,  Karin Dahlman-Wright ,  Staffan Lake ,  Wyeth Wasserman

    IPC分类号： C12Q001/68 ,  G06F019/00 ,  G01N033/48 ,  G01N033/50 ,  C07H021/04 ,  C12N009/22 ,  C12P021/02 ,  C12N005/06

    CPC分类号： C12N15/11 ,  C07K14/4701 ,  C07K14/4702 ,  C07K2319/00 ,  C12N15/85 ,  C12N2830/002

    摘要： The present invention is directed to a novel Afx response element comprising the nucleotide sequence AACATGTT, said nucleotide sequence having a DNA binding site for the human fork head transkription factor Afx. The invention also relates to the use of the Afx response element in the screening for genes as diabetes drug targets and in the bioinformatic analysis of the human genome, said genes in turn being useful in other screening methods for compounds modifying the insulin receptor signaling pathway. A further aspect of the invention is a vector construct comprising the novel nucleotide sequence, a host cell transformed with said vector construct as well as the fusion protein expressed by said host cell.

    摘要翻译： 本发明涉及包含核苷酸序列AACATGTT的新型Afx应答元件，所述核苷酸序列具有人叉头转录因子Afx的DNA结合位点。 本发明还涉及Afx应答元件在筛选基因作为糖尿病药物靶标和在人类基因组的生物信息学分析中的用途，所述基因又可用于修饰胰岛素受体信号通路的化合物的其它筛选方法。 本发明的另一方面是载体构建体，其包含新的核苷酸序列，用所述载体构建体转化的宿主细胞以及由所述宿主细胞表达的融合蛋白。